{"title":"Towards the future of Polish hematology: perspectives after 31st Meeting of Polish Society of Hematologists and Transfusiologists","authors":"Jan Styczyński","doi":"10.5603/ahp.97715","DOIUrl":null,"url":null,"abstract":"The biannual Congress of the Polish Society of Hematology and Transfusion Medicine is the most important event for all those involved in hematology and transfusiology. Between 14 and 16 September 2023, almost 1,300 attendees met in Katowice to discuss progress in these disciplines. Nowadays, the results of therapy of hematological malignancies in Poland are almost the same as the European average value. This is the result of hard work by the national working groups as well as international collaboration. Since 2021, Polish hematology has achieved great progress in therapy with the use of chimeric antigen receptor T-cell therapy. Also, a number of new compounds for hematological disorders, and supportive therapy, have been introduced in Poland, either within clinical trials or reimbursed by the National Health Fund. Even so, many patients still suffer unmet medical needs. Several important compounds, already licensed, are awaiting reimbursement. New cellular technologies are in the pipeline. The reimbursement of more therapies is desired, and further progress in diagnostic and therapeutic methods is required.","PeriodicalId":35805,"journal":{"name":"Acta Haematologica Polonica","volume":"82 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Haematologica Polonica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/ahp.97715","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
The biannual Congress of the Polish Society of Hematology and Transfusion Medicine is the most important event for all those involved in hematology and transfusiology. Between 14 and 16 September 2023, almost 1,300 attendees met in Katowice to discuss progress in these disciplines. Nowadays, the results of therapy of hematological malignancies in Poland are almost the same as the European average value. This is the result of hard work by the national working groups as well as international collaboration. Since 2021, Polish hematology has achieved great progress in therapy with the use of chimeric antigen receptor T-cell therapy. Also, a number of new compounds for hematological disorders, and supportive therapy, have been introduced in Poland, either within clinical trials or reimbursed by the National Health Fund. Even so, many patients still suffer unmet medical needs. Several important compounds, already licensed, are awaiting reimbursement. New cellular technologies are in the pipeline. The reimbursement of more therapies is desired, and further progress in diagnostic and therapeutic methods is required.